Wolchok JD (2015) PD-1 blockers. Cell 162(5):937

Article  CAS  PubMed  Google Scholar 

Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413–1422

Article  CAS  PubMed  Google Scholar 

Cascone T, William WN Jr, Weissferdt A et al (2021) Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504–514

Article  CAS  PubMed  PubMed Central  Google Scholar 

Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial [published correction appears in Lancet. Lancet 398(10308):1344–1357

Rothlin CV, Ghosh S (2020) Lifting the innate immune barriers to antitumor immunity. J Immunother Cancer 8(1):e000695

Article  PubMed  PubMed Central  Google Scholar 

Emens LA, Ascierto PA, Darcy PK et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116–129

Article  CAS  PubMed  Google Scholar 

Guo CW, Alexander M, Dib Y et al (2020) A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer 124:15–24

Article  CAS  PubMed  Google Scholar 

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447–e458

Article  CAS  PubMed  Google Scholar 

Liu Y, Wu W (2020) Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. Asia Pac J Clin Oncol 16(4):232–240

Article  PubMed  PubMed Central  Google Scholar 

Ball S, Ghosh RK, Wongsaengsak S et al (2019) Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week [published correction appears in J Am Coll Cardiol. 2019 Nov 26;74(21):2711–2712]. J Am Coll Cardiol 74(13):1714–1727

Liu S, Chan J, Brinc D et al (2020) Immune checkpoint inhibitor-associated myocarditis with persistent troponin elevation despite abatacept and prolonged immunosuppression. JACC CardioOncol 2(5):800–804 (Published 2020 Dec 15)

Article  PubMed  PubMed Central  Google Scholar 

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933

Article  PubMed  PubMed Central  Google Scholar 

van der Linden N, Klinkenberg LJJ, Bekers O et al (2016) Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: a meta-analysis. Medicine (Baltimore) 95(52):e5703

Article  Google Scholar 

Cardinale D, Sandri MT (2010) Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53(2):121–129

Article  CAS  PubMed  Google Scholar 

Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36(2):517–522

Article  CAS  PubMed  Google Scholar 

Lyon A, Lopez-Fernandez T, Couch L et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 00:1–133

Google Scholar 

Lyon A, Dent S, Stanway S et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22(11):1945–1960

Article  PubMed  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227–3337

Article  PubMed  Google Scholar 

Lang RM, Bierig M, Devereux RB et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108

Article  PubMed  Google Scholar 

Lehmann LH, Cautela J, Palaskas N et al (2021) Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol 6(11):1329–1337

Article  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 Mar;22(3):e92]. Lancet Oncol 22(2):198–211

Peleg Hasson S, Arnold J, Merdler I et al (2021) Cancer therapeutics-related cardiac dysfunction in patients treated with immune checkpoint inhibitors: an understudied manifestation. J Immunother 44(5):179–184

Article  CAS  PubMed  Google Scholar 

Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474–2481

Article  CAS  PubMed  Google Scholar 

Petricciuolo S, Delle Donne MG, Aimo A, Chella A, De Caterina R (2021) Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. Eur J Clin Investig 51(4):e13400

Article  CAS  Google Scholar 

Waliany S, Neal JW, Reddy S et al (2021) Myocarditis surveillance with high-sensitivity troponin i during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol 3(1):137–139

Article  PubMed  PubMed Central  Google Scholar 

Rini BI, Moslehi JJ, Bonaca M et al (2022) Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN Renal 101 trial [published online ahead of print, 2022 Mar 3]. J Clin Oncol JCO2101806